Abstract
Glucocorticoids (GC) play a fundamental role in controlling physiologic homeostasis and, when present in excess, can have a detrimental impact on glucose control, blood pressure and lipid levels. The oxidoreductase 11β- hydroxysteroid dehydrogenase type 1 (11β-HSD1) mainly catalyzes the intracellular regeneration of active GCs (cortisol, corticosterone) from inert inactive 11-keto forms (cortisone) in liver, adipose tissue and brain, amplifying local GC action. Multiple lines of evidence have indicated that 11β-HSD1-mediated intracellular cortisol production may have a pathogenic role in type 2 diabetes and its co-morbidities. The 11β-HSD1 becomes a novel target for anti-type 2 diabetes drug developments, and inhibition of 11β-HSD1 offers a potential therapy to attenuate the type 2 diabetes. In the past several years, a lot of 11β-HSD1 inhibitors have been designed, synthesized, screened and discovered. Lowering intracellular glucocorticoid concentrations through administration of small molecule 11β-HSD1 selective inhibitors, significantly attenuates the signs and symptoms of disease in preclinical animal models and clinical trials of diabetes and metabolic syndrome. Among published inhibitors, DIO-902 from DiObex Inc. and INCB13739 from Incyte Inc. are now being investigated under Phase 2B clinical trials. However, the selectivity of current selective 11β-HSD1 inhibitors has been just focused on the difference between 11β-HSD1 and 11β-HSD2. They inhibit the bi-directional activities of 11β-HSD1, both 11β-HSD1 reductase (major) and oxidase (minor). In our lab, we have recently found novel chemicals that not only inhibit 11β-HSD1 reductase activity but also increase its oxidase activity without inhibition against 11β-HSD2. We propose that this dual modulation on 11β-HSD1 may provide a better therapeutic strategy for type 2 diabetes.
Keywords: 11β-HSD1 inhibitor, selectivity, type 2 diabetes, clinical trial, dual modulation
Current Medicinal Chemistry
Title: 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors as Promising Therapeutic Drugs for Diabetes: Status and Development
Volume: 17 Issue: 5
Author(s): R. Ge, Y. Huang, G. Liang and X. Li
Affiliation:
Keywords: 11β-HSD1 inhibitor, selectivity, type 2 diabetes, clinical trial, dual modulation
Abstract: Glucocorticoids (GC) play a fundamental role in controlling physiologic homeostasis and, when present in excess, can have a detrimental impact on glucose control, blood pressure and lipid levels. The oxidoreductase 11β- hydroxysteroid dehydrogenase type 1 (11β-HSD1) mainly catalyzes the intracellular regeneration of active GCs (cortisol, corticosterone) from inert inactive 11-keto forms (cortisone) in liver, adipose tissue and brain, amplifying local GC action. Multiple lines of evidence have indicated that 11β-HSD1-mediated intracellular cortisol production may have a pathogenic role in type 2 diabetes and its co-morbidities. The 11β-HSD1 becomes a novel target for anti-type 2 diabetes drug developments, and inhibition of 11β-HSD1 offers a potential therapy to attenuate the type 2 diabetes. In the past several years, a lot of 11β-HSD1 inhibitors have been designed, synthesized, screened and discovered. Lowering intracellular glucocorticoid concentrations through administration of small molecule 11β-HSD1 selective inhibitors, significantly attenuates the signs and symptoms of disease in preclinical animal models and clinical trials of diabetes and metabolic syndrome. Among published inhibitors, DIO-902 from DiObex Inc. and INCB13739 from Incyte Inc. are now being investigated under Phase 2B clinical trials. However, the selectivity of current selective 11β-HSD1 inhibitors has been just focused on the difference between 11β-HSD1 and 11β-HSD2. They inhibit the bi-directional activities of 11β-HSD1, both 11β-HSD1 reductase (major) and oxidase (minor). In our lab, we have recently found novel chemicals that not only inhibit 11β-HSD1 reductase activity but also increase its oxidase activity without inhibition against 11β-HSD2. We propose that this dual modulation on 11β-HSD1 may provide a better therapeutic strategy for type 2 diabetes.
Export Options
About this article
Cite this article as:
Ge R., Huang Y., Liang G. and Li X., 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors as Promising Therapeutic Drugs for Diabetes: Status and Development, Current Medicinal Chemistry 2010; 17 (5) . https://dx.doi.org/10.2174/092986710790226147
DOI https://dx.doi.org/10.2174/092986710790226147 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Music Therapy on Psychological Symptoms and Heart Rate Variability in Patients with Dementia. A Pilot Study
Current Aging Science Effects of the Natural Isoflavonoid Genistein on Growth, Signaling Pathways and Gene Expression of Matrix Macromolecules by Breast Cancer Cells
Mini-Reviews in Medicinal Chemistry Curcumin: the Yellow Molecule with Pleiotropic Biological Effects
Letters in Drug Design & Discovery Editorial [Hot Topic: Natural Products for the Healthy Heart (Guest Editor : Dipak K. Das)]
Current Pharmaceutical Biotechnology Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Why are People with “Poor Lung Function” At Increased Atherothrombotic Risk?A Critical Review with Potential Therapeutic Indications
Current Vascular Pharmacology The Entero-Hepatic Nuclear Receptors Integrate Cholesterol, Lipid, and Bile Acid Homeostasis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Role of Omega-3 Polyunsaturated Fatty Acids Supplementation in Childhood: A Review
Recent Patents on Cardiovascular Drug Discovery A Review of QSAR studies to Discover New Drug-like Compounds Actives Against Leishmaniasis and Trypanosomiasis
Current Topics in Medicinal Chemistry Review of Progress in Predicting Protein Methylation Sites
Current Organic Chemistry Are Cerebrovascular White Matter Lesions an Early Sign of Vascular Cognitive Impairment and Vascular Dementia?
Vascular Disease Prevention (Discontinued) Chloride Channels − New Targets for the Prevention of Stroke
Current Vascular Pharmacology Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook
Current Drug Delivery Drugs that Activate Specific Nitric Oxide Sensitive Guanylyl Cyclase Isoforms Independent of Nitric Oxide Release
Current Medicinal Chemistry Subject Index To Volum 2
Current Diabetes Reviews Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Cardiovascular Drugs Inducing QT Prolongation: Facts and Evidence
Current Drug Safety The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Redox Status in Periodontal and Systemic Inflammatory Conditions Including Associated Neoplasias: Antioxidants as Adjunctive Therapy?
Infectious Disorders - Drug Targets